Participants
organ prolapse stage II, dyspareunia, breast cancer
RECRUITMENT, INTRAEPITHELIAL NEOPLASM, BREAST CANCER, DYSPAREUNIA, INFECTION, VAGINA, GENITAL CANCER
The study was conducted in the Hospital Clinic of Barcelona, Spain. The inclusion criteria were survivors of breast cancer aged 30 years and older receiving aromatase inhibitors (for ≥6 months); menopause, signs or symptoms of GSM with dyspareunia, and vaginal pH of 5 or greater; and self-reported willingness to be sexually active. The exclusion criteria included use of vaginal moisturizers or lubricants in the last 30 days; vaginal hormonal treatment in the last 6 months; use of radiofrequency, laser treatment, hyaluronic acid, or lipofilling in the vagina in the last 2 years; ospemifene treatment; intraepithelial neoplasm of cervix, vagina, or vulva; active genital tract infection; prior treatment for genital cancer; organ prolapse stage II or greater; and positive test results for human papillomavirus. Recruitment began in October 2020 and finished in September 2021. Ethnicity was self-reported by patients and assessed to describe the cohort.